Hyb & Seq Single Molecule Chemistry Sequences Oncogenes from FFPE Samples with High Accuracy and Simple Workflow Free of Library, Enzymes and Amplification
3D Biology Enables Simultaneous Detection of Somatic DNA Mutations and Expressed Fusion Transcripts plus Expression Profiling of Proteins from Lung-Tumor FFPE Samples
Digital Spatial Profiling of RNA and Protein Expression in Tumor Microenvironment from FFPE Tissue Sections
"The capabilities highlighted this week are the product of an unprecedented period of innovation at
Hyb & Seq
The Hyb & Seq chemistry is designed to enable a workflow that is simpler and faster than current sequencing methods due to the absence of library preparation, enzymes and amplification. Hyb & Seq's simple workflow and compatibility with a variety of sample types would make it ideally suited for targeted clinical sequencing. This chemistry is also unique in providing both short and long read capability simultaneously, as well as the ability to sequence both DNA and RNA in parallel. In proof-of-concept experiments using well defined reference standard reagents, Hyb & Seq chemistry demonstrated a low intrinsic error rate, and the ability to provide high consensus accuracy at low coverage by non-destructively sequencing the same native molecule multiple times.
"Hyb & Seq is a brand-new sequencing chemistry, based entirely on hybridization. It offers high accuracy, flexibility, and simplicity that potentially enable a wide range of clinical applications where rapid sample-to-answer capability is advantageous," stated
Hyb & Seq chemistry was described in one oral presentation by
- Total processing time from FFPE curls to start of sequencing was under 60 minutes, with total hands-on time of less than 15 minutes
- Current un-optimized target capture from one to three FFPE curls (10 microns thickness) was sufficient for sequencing with no PCR amplification
- Targeted sequencing of 11-plex oncogene panel, yielding QV40 sequence quality on bases with 5x coverage
- Simultaneous direct sequencing of DNA and RNA using as little as 1 to 10 ng of total RNA
- Long-read capability, with reads up to 33kB in length demonstrated to date and no theoretical upper limit to read length
- Two separate and independent assemblers developed to date, yielding similar results
Hyb & Seq technology's simplicity, flexibility, and accuracy offers an ideal sample-to-answer solution for the sequencing lab. Hyb & Seq technology is currently for research use only and is not for use in diagnostic procedures. The company is currently evaluating alternatives for the further development of the Hyb & Seq instrument, including corporate and academic partnerships.
3D Biology enables a unique application of the company's proprietary optical barcoding technology for measurement of DNA, RNA, and protein simultaneously in a single experiment. 3D Biology applications enable researchers to make entirely new observations about cancer biology while maximizing the data generated from precious samples. 3D Biology assays are currently commercially available under NanoString's Vantage 3D™ line of products.
3D Biology results were presented by
3D Biology assays are for research use only and are not for use in diagnostic procedures.
Digital Spatial Profiling
DSP technology was described in a poster titled Spatially resolved, multiplexed digital characterization of RNA and protein expression in FFPE tissue sections: Application to high-plex profiling of tumor microenvironments.
Other poster presentations included:
#205: Direct single-molecule RNA sequencing without cDNA conversion using Hyb & SeqTM chemistry -
#302: Single-molecule long read sequencing using Hyb & Seq™ chemistry -
#705: ShortStack™ Technology: Accurate, reference-guided assembly of Hyb & Seq ™ reads for
targeted sequencing to resolve short nucleotide variants and InDels -
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the expected performance of the company's Hyb & Seq chemistry and its potential superiority to existing sequencing methods, the company's Hyb & Seq chemistry's potential role as the basis for development of a DNA-sequencing instrument for clinical applications, the commercial potential of the company's Hyb & Seq chemistry and the anticipated timing for the commercial release of the DSP instrument. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include market acceptance of our products; delays or denials of regulatory approvals or clearances for products or applications; delays or denials of reimbursement for diagnostic products; the impact of competition; the impact of expanded sales, marketing, product development and clinical activities on operating expenses; delays or other unforeseen problems with respect to manufacturing, product development or clinical studies; adverse conditions in the general domestic and global economic markets; as well as the other risks set forth in the company's filings with the
Doug FarrellVice President, Investor Relations & Corporate Communications firstname.lastname@example.org Phone: 206-602-1768
News Provided by Acquire Media